Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the ...

Citius Oncology, Inc. ("Citius Oncology" or "the Company") (Nasdaq: CTOR), a majority-owned subsidiary of Citius ...

Citius Pharmaceuticals shares are trading lower by 15% during Wednesday's session. The company announced a $3 million ...

Citius Pharmaceuticals (CTXR) announced that it has entered into definitive agreements for the purchase of an aggregate of 743,496 shares of ...

After nabbing an FDA approval last summer for its T-cell lymphoma treatment Lymphir, Citius Oncology is eyeing strategic ...

Citius Pharmaceuticals (CTXR) and its oncology-focused subsidiary, Citius Oncology (CTOR), announced progress in preparations for the ...

Nandita Vijayasimha, Bengaluru Thursday, January 2, 2025, 08:00 Hrs [IST] ...

At the second attempt, the FDA has approved Citius Pharmaceuticals' marketing application for Lymphir, a new version of a lymphoma therapy withdrawn from sale several years ago. The US regulator ...

I-Mab halts CD73 program to focus on givastomig, General Proximity emerges with $16M for undruggable proteins, PBS Biotech raises $17M, Citius explores sale ...

World 800m champion Marco Arop has explained why he feels he has the capabilities to lower David Rudha’s 13-year world record, shedding light on the possible event to do it from.

Heartland Dental, the nation's leading dental support organization, is pleased to announce the appointment of Sherianne James ...